The proper question to ask management at ACTC is has the interim top line data been submitted to NEJM for publication?
If no:
Has the iTLD been submitted to any journal for peer review and publication?
If no:
Are you aware that there are researchers misleading investors at bio conferences on this matter?
If yes:
Has the article been accepted for publication or is it still under peer review, and to which journal?
then you can simply tell by what they say where it is.
Maybe its accepted with revision. If so, are the revisions completed and resubmitted, or are you waiting to resubmit them until after Apr 29, 2014? If so, why?
:)